# Supplements and Natural Remedies for OCD: Research Report

**Scout üîç Research Report | February 2026**

---

## Executive Summary

This report reviews peer-reviewed evidence on supplements and natural remedies studied for Obsessive-Compulsive Disorder (OCD). The evidence is **mixed overall**, with most supplements showing preliminary or inconclusive results. The most studied supplement (N-acetylcysteine) has conflicting trial results, while some newer agents (saffron/crocin, 5-HTP, L-carnosine) show preliminary promise warranting further investigation.

**‚ö†Ô∏è Important Disclaimer**: This is a research summary, not medical advice. OCD is a serious condition requiring professional treatment. Always consult a psychiatrist before adding supplements, especially if taking SSRIs or other medications.

---

## TIER 1: MOST EVIDENCE (Multiple RCTs Available)

### 1. N-Acetylcysteine (NAC)

**What it is:** Amino acid-based nutraceutical; glutamate modulator and antioxidant precursor to glutathione

**Mechanism:** Modulates synaptic release of glutamate via cysteine-glutamate antiporter; addresses glutamatergic dysfunction implicated in OCD pathophysiology

**Evidence Level:** üü° **MIXED/INCONCLUSIVE** - Multiple RCTs with conflicting results

#### Key Studies:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Paydary et al.** | 2016 | RCT, double-blind, adjunct to fluvoxamine | 44 | 2000 mg/day | 10 weeks | ‚úÖ **POSITIVE**: Significant Y-BOCS reduction (p=0.012) |
| **Sarris et al.** | 2015 | RCT, double-blind, placebo-controlled | 44 | 3000 mg/day | 16 weeks | üü° **MIXED**: No overall effect, but significant reduction in compulsions subscale (p=0.013) |
| **Costa et al.** | 2017 | RCT, treatment-resistant OCD | 40 | 3000 mg/day | 16 weeks | ‚ùå **NEGATIVE**: No significant benefit vs placebo; may help anxiety (p=0.02) |
| **Sarris et al.** | 2022 | Phase III RCT, multi-site | 98 | 2-4g/day | 20 weeks | ‚ùå **NEGATIVE**: No evidence of efficacy |

**2022 Meta-Analysis (Kishi et al.):** Analyzed 10 NAC studies for OCD-related disorders. Found NAC **outperformed placebo in overall symptom improvement (p<0.01)**, but results were modest.

**2018 Systematic Review (Couto & Moreira):** Pooled analysis of 4 RCTs showed mean difference of 3.35 (p=0.07), "trending toward favoring NAC but not statistically significant."

**Typical Dosages in Studies:** 2000-3000 mg/day (often split into 2 doses)

**Study Context:** All studies used NAC as **adjunct to SSRIs/SRIs** (not monotherapy)

**Safety Profile:**
- Generally well-tolerated
- Most common adverse events: gastrointestinal symptoms (nausea, heartburn, abdominal pain)
- One study: abdominal pain significantly more common in NAC group (60% vs 13.3%)

**Key Citations:**
- Paydary K et al. J Clin Pharm Ther. 2016;41(2):214-9. **PMID: 26931055**
- Costa DLC et al. J Clin Psychiatry. 2017;78(7):e766-e773. **PMID: 28617566**
- Sarris J et al. CNS Drugs. 2015;29(9):801-9. **PMID: 26374743**
- Sarris J et al. Prog Neuropsychopharmacol Biol Psychiatry. 2022;117:110550. **PMID: 35304155**
- Couto JP, Moreira R. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:245-254. **PMID: 29908912**
- Kishi T et al. Transl Psychiatry. 2022;12(1):263. **PMID: 35764619**

---

### 2. Inositol (Myo-inositol)

**What it is:** Simple polyol, second-messenger precursor in phosphatidylinositol cycle

**Mechanism:** Enhances serotonin receptor signaling (5-HT2 pathway); may affect same pathways as SSRIs

**Evidence Level:** üü° **PRELIMINARY POSITIVE, BUT LIMITED REPLICATION**

#### Key Studies:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Fux et al.** | 1996 | RCT, double-blind, crossover | 13 | 18 g/day | 6 weeks each | ‚úÖ **POSITIVE**: Significantly lower Y-BOCS scores on inositol vs placebo |
| **Seedat & Stein** | 1999 | Open trial, adjunct to SRIs | 10 | 18 g/day | 6 weeks | ‚ùå **NEGATIVE**: No response in treatment-refractory patients |

**2014 Meta-Analysis (Mukai et al.):**
- Analyzed 4 RCTs for anxiety disorders (including 2 OCD studies, n=70)
- **No statistically significant effects** of inositol on OCD symptoms
- Small sample sizes limited conclusions

**Typical Dosage:** 12-18 g/day (high doses required)

**Study Context:** Studied as both **monotherapy** and **adjunct**

**Safety Profile:**
- Generally well-tolerated
- May cause mild gastrointestinal upset
- No known serious interactions with SSRIs

**Key Citations:**
- Fux M et al. Am J Psychiatry. 1996;153(9):1219-21. **PMID: 8780431**
- Seedat S, Stein DJ. Int Clin Psychopharmacol. 1999;14(6):353-6. **PMID: 10565802**
- Mukai T et al. Hum Psychopharmacol. 2014;29(1):55-63. **PMID: 24424706**

---

## TIER 2: PROMISING PRELIMINARY EVIDENCE (Limited RCTs)

### 3. Saffron (Crocus sativus) / Crocin

**What it is:** Spice derived from Crocus sativus flower; crocin is its active carotenoid component

**Mechanism:** Multiple pathways - serotonergic, dopaminergic, glutamatergic modulation; antioxidant effects

**Evidence Level:** üü¢ **PROMISING PRELIMINARY** - Comparable to SSRIs in mild-moderate OCD

#### Key Studies:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Esalatmanesh et al.** | 2017 | RCT, saffron vs fluvoxamine | 46 | 30 mg/day saffron | 10 weeks | ‚úÖ Saffron **as effective as fluvoxamine** for mild-moderate OCD |
| **Kazemi et al.** | 2021 | RCT, crocin vs fluoxetine | 50 | 15-30 mg/day crocin | 8 weeks | ‚úÖ Crocin **as effective as fluoxetine** with fewer side effects |

**Typical Dosages:** Saffron extract 30 mg/day; Crocin 15-30 mg/day

**Study Context:** Studied as **monotherapy** in mild-to-moderate OCD

**‚ö†Ô∏è Safety Concerns:**
- May have serotonergic effects - potential interaction risk with SSRIs (theoretical)
- Generally well-tolerated in studies
- Fewer adverse effects than SSRIs in comparative trials

**Key Citations:**
- Esalatmanesh S et al. Iran J Psychiatry. 2017;12(3):154-162. **PMID: 29062366** (Free PMC)
- Kazemi F et al. Hum Psychopharmacol. 2021;36(4):e2780. **PMID: 33599345**

---

### 4. 5-Hydroxytryptophan (5-HTP)

**What it is:** Immediate precursor to serotonin (5-HT); derived from tryptophan

**Mechanism:** Increases serotonin synthesis and availability

**Evidence Level:** üü¢ **PROMISING PRELIMINARY** - One positive RCT

#### Key Study:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Yousefzadeh et al.** | 2020 | RCT, double-blind, adjunct to fluoxetine | 60 | 200 mg/day (100mg BID) | 12 weeks | ‚úÖ **POSITIVE**: Significant improvement in total Y-BOCS (p<0.001), obsession (p=0.001), and compulsion (p=0.002) subscales |

**Typical Dosage:** 200 mg/day (100 mg twice daily)

**Study Context:** **Adjunct to fluoxetine** (20-60 mg/day)

**‚ö†Ô∏è CRITICAL SAFETY CONCERNS:**
- **HIGH RISK with SSRIs** - can cause serotonin syndrome
- Must not combine with SSRIs without medical supervision
- Study was conducted under controlled conditions with monitoring

**Key Citation:**
- Yousefzadeh F et al. Int Clin Psychopharmacol. 2020;35(5):254-262. **PMID: 32541380**

---

### 5. L-Carnosine

**What it is:** Dipeptide (Œ≤-alanine + histidine); found naturally in muscle and brain tissue

**Mechanism:** Glutamate modulator; neuroprotective; antioxidant

**Evidence Level:** üü¢ **PROMISING PRELIMINARY** - One positive RCT

#### Key Study:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Arabzadeh et al.** | 2017 | RCT, double-blind, adjunct to fluvoxamine | 44 | 500-1000 mg/day | 10 weeks | ‚úÖ **POSITIVE**: Significant reduction in Y-BOCS total (p<0.001), obsession (p=0.01), compulsion (p=0.01) |

**Typical Dosage:** 500-1000 mg/day

**Study Context:** **Adjunct to fluvoxamine**

**Safety Profile:** Well-tolerated in study; no significant adverse effects reported

**Key Citation:**
- Arabzadeh S et al. Hum Psychopharmacol. 2017;32(4). **PMID: 28485008**

---

### 6. Glycine

**What it is:** Simple amino acid; NMDA glutamate receptor agonist

**Mechanism:** Modulates glutamatergic neurotransmission

**Evidence Level:** üü° **PRELIMINARY, UNDERPOWERED**

#### Key Study:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Greenberg et al.** | 2009 | RCT, double-blind, adjunctive | 24 (only 14 evaluable) | Up to 60 g/day | 12 weeks | üü° **TREND POSITIVE**: 6.04 point Y-BOCS reduction vs 1.00 for placebo (p=0.053 - not quite significant) |

**Major Limitations:**
- High dropout rate due to palatability issues (taste/nausea)
- Extremely high doses required (60 g/day)
- Small evaluable sample

**Safety Profile:**
- Main issue is tolerability, not safety
- Gastrointestinal upset common at high doses

**Key Citation:**
- Greenberg WM et al. J Psychiatr Res. 2009;43(6):664-70. **PMID: 19046587**

---

### 7. Valerian Root (Valeriana officinalis)

**What it is:** Traditional herbal sedative/anxiolytic

**Mechanism:** GABAergic activity

**Evidence Level:** üü° **VERY PRELIMINARY** - Single small study

#### Key Study:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Pakseresht et al.** | 2011 | RCT, double-blind, vs placebo | 31 | 765 mg/day | 8 weeks | ‚úÖ **POSITIVE**: Significant difference vs placebo (p<0.001) |

**Limitations:** Single small study; no replication

**Safety:** Somnolence was more common in valerian group (p=0.02)

**Key Citation:**
- Pakseresht S et al. J Complement Integr Med. 2011. **PMID: 22718671**

---

## TIER 3: NEGATIVE OR INSUFFICIENT EVIDENCE

### 8. St. John's Wort (Hypericum perforatum)

**What it is:** Traditional herbal antidepressant

**Mechanism:** Multiple - serotonergic, dopaminergic, GABAergic activity

**Evidence Level:** ‚ùå **NEGATIVE** - Does not appear effective for OCD

#### Key Studies:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Taylor & Kobak** | 2000 | Open-label trial | - | - | 12 weeks | Initial positive results |
| **Kobak et al.** | 2005 | RCT, double-blind, vs placebo | 60 | 600-1800 mg/day | 12 weeks | ‚ùå **NEGATIVE**: No difference from placebo |

**Conclusion:** The 2011 Camfield review states: "Currently the balance of clinical evidence does not support the use of St. John's wort in OCD."

**‚ö†Ô∏è SAFETY WARNING:**
- **DANGEROUS with SSRIs** - can cause serotonin syndrome
- Many drug-drug interactions (induces CYP enzymes)

**Key Citations:**
- Kobak KA et al. Int Clin Psychopharmacol. 2005;20(6):299-304. **PMID: 16192837**
- Taylor LH, Kobak KA. J Clin Psychiatry. 2000;61(8):575-8. **PMID: 10982200**

---

### 9. Omega-3 Fatty Acids (EPA)

**What it is:** Essential fatty acids; EPA (eicosapentaenoic acid)

**Evidence Level:** ‚ùå **NEGATIVE** - Single negative RCT

#### Key Study:

| Study | Year | Design | N | Dose | Duration | Outcome |
|-------|------|--------|---|------|----------|---------|
| **Fux et al.** | 2004 | RCT, crossover, adjunctive EPA | 11 | 2 g/day | 6 weeks each | ‚ùå **NEGATIVE**: No benefit over placebo |

**Key Citation:**
- Fux M et al. J Psychiatr Res. 2004;38(3):323-5. **PMID: 15003438**

---

### 10. Vitamin D

**Evidence Level:** ‚ùå **NO TREATMENT TRIALS** - Only observational studies

**What we know:**
- OCD patients show **lower vitamin D levels** than controls (Marazziti et al., 2021; Yazici et al., 2018)
- No RCTs testing vitamin D supplementation for OCD symptoms
- Deficiency may be a marker, not necessarily causal

**Key Citations:**
- Marazziti D et al. CNS Spectr. 2023;28(5):606-613. **PMID: 34551844**
- Yazici KU et al. Nord J Psychiatry. 2018;72(3):173-178. **PMID: 29168423**

---

### 11. Magnesium, Zinc, B Vitamins

**Evidence Level:** ‚ùå **NO DIRECT OCD TRIALS**

One open-label pilot study (TRON study, Sarris et al. 2022) tested a **combination formula** containing NAC, L-theanine, zinc, magnesium, pyridoxal-5'-phosphate (B6), and selenium in 28 treatment-resistant OCD patients. Results showed significant Y-BOCS reduction (-7.13 points), but:
- No placebo control
- Cannot attribute effects to individual ingredients
- 23% response rate

**Key Citation:**
- Sarris J et al. CNS Spectr. 2022;27(5):588-597. **PMID: 34165060**

---

### 12. L-Theanine

**Evidence Level:** ‚ùå **NO DIRECT OCD TRIALS**

- Only studied as part of combination formula (TRON study above)
- No standalone RCTs for OCD

---

### 13. Probiotics / Microbiome Interventions

**Evidence Level:** ‚ùå **PRECLINICAL ONLY** for OCD

- Multiple reviews suggest gut-brain axis involvement in OCD (Bendriss et al. 2023; Kamble & Dandekar 2023)
- Animal studies show probiotic interventions reduce OCD-like behaviors
- **No human clinical trials completed** for OCD specifically

**Key Citations:**
- Bendriss G et al. Int J Mol Sci. 2023;24(15):11978. **PMID: 37569349**
- Kamble SR, Dandekar MP. Eur J Pharmacol. 2023;957:176014. **PMID: 37619786**

---

### 14. Milk Thistle (Silymarin)

**Evidence Level:** ‚ùå **NO DIRECT OCD TRIALS**

- Mentioned in 2011 Camfield review as having theoretical potential
- Included in 2022 meta-analysis (Kishi et al.) with one study
- No standalone RCT found for OCD

---

### 15. Curcumin/Turmeric

**Evidence Level:** ‚ùå **NO OCD TRIALS**

- 2017 review (Lopresti) covers neuropsychiatric uses but notes no OCD-specific studies

---

### 16. Ashwagandha (Withania somnifera)

**Evidence Level:** ‚ùå **NO OCD TRIALS**

- Mentioned in herbal medicine reviews but no human OCD trials identified

---

## COMPREHENSIVE EVIDENCE TABLE

| Supplement | Evidence Level | RCTs | Best Dosage | Context | Recommendation |
|------------|----------------|------|-------------|---------|----------------|
| **N-Acetylcysteine** | Mixed | 5+ | 2000-3000 mg/day | Adjunct | May try as add-on; modest benefit if any |
| **Inositol** | Mixed | 2 | 18 g/day | Both | Small early positive study not replicated |
| **Saffron/Crocin** | Promising | 2 | 30 mg/day | Monotherapy | Promising for mild-moderate; needs replication |
| **5-HTP** | Promising | 1 | 200 mg/day | Adjunct | ‚ö†Ô∏è Serotonin syndrome risk with SSRIs |
| **L-Carnosine** | Promising | 1 | 500-1000 mg/day | Adjunct | Promising; needs replication |
| **Glycine** | Preliminary | 1 | 60 g/day | Adjunct | Tolerability issues; needs better formulation |
| **Valerian** | Preliminary | 1 | 765 mg/day | Monotherapy | Single small study; needs replication |
| **St. John's Wort** | Negative | 1 | - | - | ‚ùå Not recommended; no efficacy, SSRI interaction risk |
| **Omega-3 (EPA)** | Negative | 1 | - | - | ‚ùå Not effective for OCD |
| **Vitamin D** | Unknown | 0 | - | - | No treatment trials |
| **Probiotics** | Unknown | 0 | - | - | Preclinical only |

---

## SAFETY CONSIDERATIONS

### SSRI Interactions - HIGH RISK:
- **5-HTP**: Can cause serotonin syndrome - DO NOT combine without supervision
- **St. John's Wort**: Serotonin syndrome risk + induces drug metabolism

### SSRI Interactions - MODERATE/THEORETICAL:
- **Saffron**: May have serotonergic effects
- **Inositol**: Affects serotonin pathways (generally considered safe)

### Generally Safe with SSRIs:
- N-Acetylcysteine
- L-Carnosine
- Glycine
- Valerian
- Omega-3s
- Vitamins/minerals

---

## KEY REVIEW ARTICLES

1. **Camfield DA et al.** "Nutraceuticals in the treatment of OCD: a review of mechanistic and clinical evidence." Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):887-95. **PMID: 21352883**

2. **Ayati Z et al.** "Herbal medicines and phytochemicals for obsessive-compulsive disorder." Phytother Res. 2020;34(8):1889-1901. **PMID: 32124509**

3. **Kishi T et al.** "Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis." Transl Psychiatry. 2022;12(1):263. **PMID: 35764619**

4. **Gautam M.** "Clinical Recommendations for Augmentation Agents in OCD Partially Responsive to SRIs." J Clin Psychopharmacol. 2023;43(4):369-377. **PMID: 37335203**

5. **Kuygun Karcƒ± C, G√ºl Celik G.** "Nutritional and herbal supplements in the treatment of OCD." Gen Psychiatr. 2020;33(2):e100159. **PMID: 32215361** (Free PMC)

---

## CONCLUSIONS

1. **No supplement has strong evidence** supporting standalone use for OCD

2. **N-Acetylcysteine** is the most studied but results are mixed; may have modest benefit as add-on therapy, particularly for compulsions; well-tolerated

3. **Saffron/Crocin** shows intriguing preliminary evidence as potentially comparable to SSRIs for mild-moderate OCD, but only 2 trials exist

4. **5-HTP** showed strong results in one trial but carries serious serotonin syndrome risk with SSRIs

5. **L-Carnosine** is promising based on one positive RCT; good safety profile

6. **Inositol** had one early positive study but meta-analysis shows no significant effect

7. **St. John's Wort and Omega-3s** are NOT effective based on current evidence

8. **Vitamin D, probiotics, curcumin, ashwagandha** lack any OCD-specific treatment trials

9. **First-line treatment remains SSRIs + CBT (ERP)** - supplements should only be considered as adjuncts or for treatment-resistant cases under medical supervision

---

*Report compiled from PubMed database searches, February 2026*

---

**AI Disclosure:** This document was researched and compiled with AI assistance (Claude/OpenClaw). All cited studies are real peer-reviewed publications indexed in PubMed. Always verify claims with original sources and consult healthcare professionals.
